Illumina's recent announcement of the MiSeq i100 series is seen as a significant step in expanding its sequencing TAM. While the company has not provided specific guidance on expected pull-through ...

Illumina is a prominent entity in the genomic sequencing market, providing advanced DNA sequencing ... The favorable court ...

Illumina employees have been showing their commitment to early cancer detection and advancing research and treatment by ...

Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ETCorporate ParticipantsSalli Schwartz - Vice President of ...

ILMN is likely to have benefited from the significant step-up in consumables with growing customer activity on NovaSeq X. Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array ...

New strategies promise to streamline workflows, conserve consumables, increase productivity, and enhance reproducibility.

While there have been substantial advancements in the field of oncology and the treatment of the disease, keeping the cancer ...

Researchers link microscopic protein structures and cellular interactions to individual differences in brain connectivity, ...

From growing up in Shallcross to attending the University of Oxford in the United Kingdom, Kumeren Govender has obtained his ...

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

Illumina's margin expansion and a coming revenue recovery should help the stock multiples re-rate toward life science ...